Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

2.0%

7 terminated/withdrawn out of 358 trials

Success Rate

89.7%

+3.2% vs industry average

Late-Stage Pipeline

8%

29 trials in Phase 3/4

Results Transparency

0%

0 of 61 completed trials have results

Key Signals

106 recruiting

Enrollment Performance

Analytics

N/A
97(40.8%)
Phase 2
70(29.4%)
Phase 1
39(16.4%)
Phase 3
21(8.8%)
Phase 4
8(3.4%)
Early Phase 1
3(1.3%)
238Total
N/A(97)
Phase 2(70)
Phase 1(39)
Phase 3(21)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (358)

Showing 20 of 358 trials
NCT07640438Phase 1Recruiting

Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ

Role: lead

NCT07635992Phase 1Not Yet Recruiting

A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV

Role: lead

NCT07621562Phase 2Not Yet Recruiting

Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer

Role: lead

NCT07616648Recruiting

Effects of Opioid Drugs on Sleep and Emotion in Patients With Moderate to Severe Cancer Pain

Role: lead

NCT05964777Not ApplicableCompleted

rTMS-tACS Stimulation on Improving Cognitive Function in Bipolar Disorder

Role: lead

NCT05929183Not ApplicableCompleted

Neuronavigation rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent

Role: lead

NCT06826469Not ApplicableNot Yet Recruiting

The Efficacy and Safety of Task-state-based Temporal Interference Stimulation (TI) in the Treatment of Patients With Depression

Role: lead

NCT07589647Not ApplicableRecruiting

Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity

Role: lead

NCT06516991Not ApplicableCompleted

Task-State-Based Temporal Interference Stimulation (TI) to Improve Depression in Patients With Bipolar Disorder

Role: lead

NCT07021508Not ApplicableRecruiting

Efficacy and Safety Assessment of Temporal Interference Stimulation to Improve Bipolar Depression

Role: lead

NCT06782763Not ApplicableCompleted

Efficacy and Safety of Task-activated rTMS in Improving Cognitive Function in Patients With Bipolar Disorder

Role: lead

NCT05129904Active Not Recruiting

Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)

Role: collaborator

NCT07537192Not ApplicableNot Yet Recruiting

Inulin-Spirulina Co-intervention for Insomnia Disorder

Role: lead

NCT07002346Phase 3Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator

NCT07554898Phase 2Recruiting

Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma

Role: collaborator

NCT07577986Phase 1Not Yet Recruiting

A Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir

Role: lead

NCT07562516Not ApplicableNot Yet Recruiting

PB-18 Probiotic for Mild to Moderate Depression

Role: lead

NCT07570680Recruiting

Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)

Role: collaborator

NCT07565623Not ApplicableNot Yet Recruiting

Prevention of AIDS With Opportunistic Infection Paradoxical IRIS

Role: collaborator

NCT07554807Phase 3Not Yet Recruiting

A Randomized, Double-blind, Placebo-controlled, Prospective, Multi-center Trial Evaluating the Improvement of Nutritional Status and Sarcopenia With Silkworm Pupa Tablets in Patients With Malignancies

Role: lead